Stock CING CINGULATE INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Cingulate Inc.

Equities

CING

US17248W2044

Market Closed - Nasdaq
Other stock markets
 01:30:00 27/06/2024 am IST 		5-day change 1st Jan Change
0.564 USD -3.75% Intraday chart for Cingulate Inc. -1.05% -92.63%
21/05 FDA Clears Cingulate to File for Marketing Approval of CTx-1301 in the Treatment of ADHD CI
08/05 Cingulate Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Cingulate and ADHD Expert Dr. Ann Childress, MD to Participate in Benzinga All Live Access Event
AQ
Cingulate Achieves Key Manufacturing Milestone in the Development of its ADHD Drug CTx-1301 in Preparation for FDA Marketing Clearance
AQ
Cingulate : Failure to Satisfy Listing Rule Form 8 K
PU
FDA Clears Cingulate to File for Marketing Approval of CTx-1301 in the Treatment of ADHD
AQ
FDA Clears Cingulate to File for Marketing Approval of CTx-1301 in the Treatment of ADHD
CI
Cingulate Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Cingulate Reports First Quarter 2024 Financial Results and Provides Clinical and Business Update
AQ
Certain Pre-Funded Warrants of Cingulate Inc. are subject to a Lock-Up Agreement Ending on 7-MAY-2024.
CI
Certain Warrants of Cingulate Inc. are subject to a Lock-Up Agreement Ending on 7-MAY-2024.
CI
Certain Stock Options of Cingulate Inc. are subject to a Lock-Up Agreement Ending on 7-MAY-2024.
CI
Certain Common Stock of Cingulate Inc. are subject to a Lock-Up Agreement Ending on 7-MAY-2024.
CI
Peter J. Werth, Successful Pharma Entrepreneur, Philanthropist, Cingulate Investor and Board Member, to be Featured with Chairman and CEO Shane J. Schaffer on Benzinga All Live Access
AQ
Cingulate to Participate in Planet MicroCap Showcase: Vegas 2024
AQ
Cingulate Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Cingulate Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Cingulate Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business Update
AQ
Cingulate to Participate in Benzinga All Live Access Event
AQ
Cingulate to Attend DCAT Week 2024 in New York City
AQ
Cingulate Appoints Jay Roberts, Bryan Lawrence, and Jeff Ervin to its Board of Directors
AQ
Cingulate Appoints Jay Roberts, Bryan Lawrence, and Jeff Ervin to Its Board of Directors
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CING Stock
  4. News Cingulate Inc.